<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174549</url>
  </required_header>
  <id_info>
    <org_study_id>LT001</org_study_id>
    <nct_id>NCT02174549</nct_id>
  </id_info>
  <brief_title>Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer</brief_title>
  <official_title>Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teclison Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teclison Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating&#xD;
      agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer&#xD;
      patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4&#xD;
      nodules are eligible. Tirapazamine will be given by intra-arterial injection before&#xD;
      embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat&#xD;
      treatment is necessary only if disease progression. Expansion cohorts are open for metastatic&#xD;
      gastrointestinal cancer and neuroendocrine tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 3+3 design for dose escalation. Each cohort will have 3-6 patients based on&#xD;
      tolerability. Patients will receive escalated doses of tirapazamine until maximally tolerated&#xD;
      dose. Embolization is performed per standard practice using Lipiodol and Gelfoam under X-ray&#xD;
      guidance. Once a suitable dose is determined, an expansion cohort of 15 patients will be&#xD;
      treated with the recommended phase 2 dose to determine preliminary efficacy. Expansion&#xD;
      cohorts include (1) hepatocellular carcinoma, (2) metastatic solid tumors with liver&#xD;
      metastasis, and (3) neuroendocrine tumor. Adverse events are evaluated by CTCAE vs. 4.0 and&#xD;
      efficacy is evaluated by MRI using modified RECIST criteria and RECIST criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, dose escalation 3+3 design; 3 expansion cohorts: hepatocellular carcinoma, advanced solid tumors and neuroendocrine tumor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the recommended phase 2 dose</measure>
    <time_frame>2 years</time_frame>
    <description>future dose used for randomzied trials</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>2 years</time_frame>
    <description>mRECIST based on mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years</time_frame>
    <description>From randomization to progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>2 years</time_frame>
    <description>PK parameter</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Gastrointestinal Cancer Metastatic</condition>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Tirapazamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirapazamine</intervention_name>
    <description>Intra-arterial injection into the tumor feeding artery</description>
    <arm_group_label>Tirapazamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial embolization (TAE)</intervention_name>
    <description>Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia</description>
    <arm_group_label>Tirapazamine</arm_group_label>
    <other_name>Lipiodol and Gelfoam as the standard embolizing agents.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Confirmed diagnosis of HCC &gt; 10 mm with a characteristic 4-phase CT or dynamic&#xD;
             contrast enhanced MRI finding showing intense arterial uptake followed by &quot;washout&quot; of&#xD;
             contrast in the venous-delayed phases per American Association for the Study of Liver&#xD;
             Disease (AASLD) criteria.&#xD;
&#xD;
          -  Patients between ages 20 and 80&#xD;
&#xD;
          -  Patients with single or multiple (2-4 nodules) HCC who are unsuitable or unwilling for&#xD;
             surgical resection or RFA. The largest tumor nodule should be less than 10 cm in the&#xD;
             largest diameter. The total volume of tumor cannot exceed 50% of liver; or patients&#xD;
             with liver metastatic gastrointestinal cancer, including neuroendocrine tumor&#xD;
&#xD;
          -  Patients are candidates for TAE or Transarterial ChemoEmbolization (TACE). No tumor&#xD;
             invasion to portal vein or thrombosis in portal vein.&#xD;
&#xD;
          -  ECOG score 0-1 with no known cardiac, pulmonary or renal dysfunction&#xD;
&#xD;
          -  Child-Pugh score group A or B7 liver functional score&#xD;
&#xD;
          -  Prior local therapies such as surgical resection, radiofrequency ablation, or alcohol&#xD;
             injection are allowed as long as tumor progresses from the prior treatment and the&#xD;
             patients are still candidates for TAE. All prior therapy must be at least 4 weeks&#xD;
             prior to enrollment and free from treatment-related toxicity.&#xD;
&#xD;
          -  No TAE/TACE in the past&#xD;
&#xD;
          -  Patients have normal organ function: ANC ≥ 1000 /µL, Hemoglobin ≥ 9 gm/dL, Platelets ≥&#xD;
             50,000 /µL, Creatinine ≤ 2 mg/dL, AST and ALT &lt; 5 X upper normal limit of the current&#xD;
             institution; bilirubin ≤ 3.0 mg/dL, PT prolongation no more than 4 sec above upper&#xD;
             limit of normal.&#xD;
&#xD;
        For the expansion cohort of neuroendocrine tumor or metastatic solid tumor with liver&#xD;
        involvement&#xD;
&#xD;
          -  Unresectable, locally advanced or metastatic, well differentiated (low or intermediate&#xD;
             grade), neuroendocrine tumors (NET).&#xD;
&#xD;
          -  Metastatic solid tumor with liver involvement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Abi-Jaoudeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>Embolization</keyword>
  <keyword>Tirapazamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirapazamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

